Home » Newsletters » BioWorld Science

BioWorld Science

May 13, 2002

View Archived Issues

Increased funding in Control Delivery Systems and Bausch & Lomb collaboration

Quilimmune-P stimulates high immune response in elderly subjects

Phase III trial of electroporation therapy in head and neck cancer

Strontium ranelate: an innovative drug for osteoporosis

Novel PTHRP analogue effective and safe in animal models of osteopenia

Tadalafil, an important new treatment option for most men with ED

Neovastat treatment transiently halts the progression of pulmonary hypertension

Improvement in glucose metabolism, GI dysfunction in diabetic rats treated with BSF-208075

SR-121463 for the management of fluid retention in heart failure

AVI-4126-eluting stents protect against neointimal thickening in porcine coronary arteries

Xcytrin studied with radiation and chemotherapy in NSCLC

Final phase II data for GPI-1485 in Parkinson's disease

Viread comparable to stavudine in treatment-naive HIV patients at 48 weeks

Wyeth to discontinue development of rPSGL-Ig for myocardial infarction

PharmaBlood antitumor vaccine in early clinical trials

Mechanism of action of traditional Indian medicine for lipid disorders elucidated

Seasonale oral contraceptive has comparable efficacy to Nordette and Levlite

Hollis-Eden updates progress of HE-2500 and HE-2200

Bayer and Medicines for Malaria Venture develop artemisone-based malaria therapy

SM047 monoclonal antibody specific for ovarian carcinomas

Protein-tyrosine-phosphatase inhibitors with application in type 2 diabetes

Compounds with potential as analgesics reported by AstraZeneca

Factor Xa inhibitors for undesired thrombosis

Inhibitors of 17beta-HSD-2 with utility in osteoporosis, etc.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.